The farnesyl transferase inhibitor (FTI) SCH66336 (lonafarnib) inhibits Rheb farnesylation and mTOR signaling. Role in FTI enhancement of taxane and tamoxifen anti-tumor activity. [electronic resource]
Producer: 20051025Description: 31101-8 p. digitalISSN:- 0021-9258
- Alkyl and Aryl Transferases -- antagonists & inhibitors
- Animals
- Antineoplastic Agents -- therapeutic use
- Bridged-Ring Compounds -- therapeutic use
- Caspases -- metabolism
- Cell Line, Tumor
- Farnesyltranstransferase
- Humans
- Monomeric GTP-Binding Proteins -- genetics
- Neoplasms -- drug therapy
- Neuropeptides -- genetics
- Phosphorylation
- Piperidines -- metabolism
- Protein Kinases -- genetics
- Protein Prenylation
- Pyridines -- metabolism
- RNA, Messenger -- metabolism
- Ras Homolog Enriched in Brain Protein
- Recombinant Fusion Proteins -- genetics
- Signal Transduction -- physiology
- TOR Serine-Threonine Kinases
- Tamoxifen -- therapeutic use
- Taxoids -- therapeutic use
No physical items for this record
Publication Type: Journal Article
There are no comments on this title.
Log in to your account to post a comment.